Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Lancet Oncology Année : 2019

Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

1 Princess Máxima Center for Pediatric Oncology [Utrecht, Netherlands]
2 Erasmus MC-Sophia Hospital [Rotterdam, Netherlands]
3 Academic Medical Center - Emma Children's Hospital [Amsterdam, Netherlands]
4 St Jude Children's Research Hospital
5 Great North Children’s Hospital [Newcastle Upon Tyne, UK]
6 NICR - Northern Institute for Cancer Research [Newcastle]
7 URMC - University of Rochester Medical Center
8 ISPM - Institute of Social and Preventive Medicine [Bern]
9 University Hospital for Children and Adolescents [Lübeck, Germany]
10 PRISM - Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192
11 Service d'Otologie et d'Otoneurologie [CHU Lille]
12 GOSHC - Great Ormond Street Hospital for Children NHS Foundation Trust [London, UK]
13 UBC - University of British Columbia
14 Stanford University
15 Sydney Children's hospital
16 OHSU - Oregon Health and Science University [Portland]
17 SickKids - The Hospital for sick children [Toronto]
18 Children’s Hospital Los Angeles [Los Angeles]
19 USC - University of Southern California
20 LSU - Louisiana State University
21 Children's Hospital at New Orleans
22 MUNI - Masaryk University [Brno]
23 Kantonsspital Aarau [Aarau, Switzerland]
24 University Hospital Basel [Basel]
25 McMaster University [Hamilton, Ontario]
26 Perth Children's Hospital [Nedlands, WA, Australia]
27 UWA - The University of Western Australia
28 University of Regensburg
29 UKM - University Hospital Münster - Universitaetsklinikum Muenster [Germany]
30 UNSW - University of New South Wales [Sydney]
31 UAB - University of Alabama at Birmingham [ Birmingham]
Kay Chang
  • Fonction : Auteur

Résumé

Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

Dates et versions

inserm-02941725 , version 1 (17-09-2020)

Identifiants

Citer

Eva Clemens, Marry van den Heuvel-Eibrink, Renée Mulder, Leontien Kremer, Melissa Hudson, et al.. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncology, 2019, 20 (1), pp.e29-e41. ⟨10.1016/S1470-2045(18)30858-1⟩. ⟨inserm-02941725⟩

Collections

INSERM UNIV-LILLE
43 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More